Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gonadotrophin-releasing Hormone (GnRH) Clear all
Completed Phase 2 Interventional Results available

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

NCT02135445
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-385, Degarelix
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 9, 2026, 10:46 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Aging and Estrogen on the Pituitary

NCT00386022
View directory record Official record
Conditions
Healthy
Interventions
GnRH, NAL-GLU GnRH antagonist, Estrogen patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Not applicable Interventional

CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)

NCT02858336
View directory record Official record
Conditions
Hormones
Interventions
NEA, DEA
Behavioral
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 10:46 AM EDT
Recruiting Phase 1 Interventional

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

NCT06631521
View directory record Official record
Conditions
Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
Interventions
Darolutamide, Relugolix, Radical Prostatectomy
Drug · Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Leuprolide in Determining the Cause of Gonadotropin Deficiency

NCT00004426
View directory record Official record
Conditions
Hypogonadism
Interventions
gonadotropin releasing hormone, leuprolide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
9 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 9, 2026, 10:46 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump

NCT07152730
View directory record Official record
Conditions
Amenorrhea, Fertility, Infertility
Interventions
Lutrepulse
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature

NCT00001190
View directory record Official record
Conditions
Dwarfism, Growth Disorder
Interventions
Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

NCT00667446
View directory record Official record
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 4 Interventional Results available

MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population

NCT02554279
View directory record Official record
Conditions
Infertility
Interventions
menotropin, recombinant FSH
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
21 Years to 35 Years · Female only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 9, 2026, 10:46 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 10:46 AM EDT
Recruiting Not applicable Interventional

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

NCT06824818
View directory record Official record
Conditions
Elderly, Prostate Cancer
Interventions
LHRH Agonist Therapy Discontinuation
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
70 Years and older · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
View directory record Official record
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 9, 2026, 10:46 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 9, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

NCT07235917
View directory record Official record
Conditions
Functional Hypothalamic Amenorrhea, FHA
Interventions
Mibavademab, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • West Hills, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

NCT01403038
View directory record Official record
Conditions
Folliculogenesis
Interventions
elagolix
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
20
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 9, 2026, 10:46 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders

NCT01165619
View directory record Official record
Conditions
Idiopathic Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 9, 2026, 10:46 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

NCT00493961
View directory record Official record
Conditions
Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Melanoma Vaccine With Peptides and Leuprolide

NCT00254397
View directory record Official record
Conditions
Melanoma
Interventions
Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 9, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

NCT06395753
View directory record Official record
Conditions
Prostate Cancer
Interventions
Debio 4228
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Mesa, Arizona • Queen Creek, Arizona • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 10:46 AM EDT
Active, not recruiting Phase 2 Interventional

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

NCT02949284
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Biological · Other + 1 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 9, 2026, 10:46 AM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 9, 2026, 10:46 AM EDT